Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy
<p>Treatment of stave IV renal cell cancer and melanoma with intravenous interleukin-2 (IL-2) is often limited by side effects, and only a minority of patients obtain sustained remissions. This editorial proposes that infusing IL-2 into the splenic artery will allow much stronger immune activa...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
IJCTO
2014-02-01
|
Series: | International Journal of Cancer Therapy and Oncology |
Subjects: | |
Online Access: | http://ijcto.org/index.php/IJCTO/article/view/80 |